1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid has been researched along with Diffuse Mixed Small and Large Cell Lymphoma in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Kang, HJ; Lee, I; Lee, KC; Lim, I; Lim, SM | 1 |
| Akhlaghi, M; Gholipour, N; Jalilian, AR; Johari-Daha, F; Khalaj, A; Khanchi, AR; Sabzevari, O; Yavari, K | 1 |
| Arksey, N; Chin, FT; Gambhir, SS; Iagaru, A; Natarajan, A | 1 |
| Chen, J; Fani, M; Forrer, F; Lohri, A; Maecke, HR; Moldenhauer, G; Müller-Brand, J; Powell, P | 1 |
| Gambhir, SS; Goris, ML; Gowrishankar, G; Iagaru, A; Natarajan, A; Nielsen, CH; Wang, S | 1 |
| Fisher, DR; Goldenberg, DM; Govindan, SV; Griffiths, GL; Sharkey, RM | 1 |
| Alavi, A; Brenner, A; Burton, J; Chatal, JF; Czuczman, MS; Goldenberg, DM; Hajjar, G; Kraeber-Bodere, F; Lamonica, D; Mahe, B; Mardirrosian, G; Matthies, A; Rogatko, A; Schuster, SJ; Sharkey, RM; Stadtmauer, EA; Toder, SP; Tsai, DE | 1 |
| DeNardo, GL; DeNardo, SJ; Kroger, LA; Meares, CF; Mirick, GR; O'Donnell, RT | 1 |
2 trial(s) available for 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Cell Line; Chelating Agents; Heterocyclic Compounds, 1-Ring; Humans; Immunoconjugates; Lutetium; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Mice; Pilot Projects; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Rituximab; Yttrium Radioisotopes | 2009 |
Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Female; Heterocyclic Compounds, 1-Ring; Humans; Indium; Isotopes; Lymphoma, Non-Hodgkin; Male; Metabolic Clearance Rate; Middle Aged; Predictive Value of Tests; Prognosis; Radioimmunotherapy; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy; Radiotherapy Dosage; Tissue Distribution; Treatment Outcome; Yttrium Radioisotopes | 2003 |
6 other study(ies) available for 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
64 Cu-DOTA-Rituximab PET/CT of B-Cell Non-Hodgkin Lymphoma for Imaging the CD20 Expression.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Fluorodeoxyglucose F18; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Rituximab | 2023 |
Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with ⁹⁰Y and ¹¹¹In for domestic radioimmunotherapy and radioscintigraphy of non-Hodgkin's lymphoma.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Cell Line, Tumor; Drug Compounding; Freeze Drying; Heterocyclic Compounds, 1-Ring; Humans; Immunoconjugates; Indium Radioisotopes; Isotope Labeling; Lymphoma, Non-Hodgkin; Male; Radioimmunotherapy; Radionuclide Imaging; Rats; Rituximab; Serum Albumin; Tissue Distribution; Yttrium Radioisotopes | 2014 |
Validation of 64Cu-DOTA-rituximab injection preparation under good manufacturing practices: a PET tracer for imaging of B-cell non-Hodgkin lymphoma.
Topics: Animals; Antibodies, Monoclonal; Antigens, CD20; Copper Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Mice; Mice, Transgenic; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Rituximab; Tomography, X-Ray Computed | 2015 |
Positron emission tomography of 64Cu-DOTA-Rituximab in a transgenic mouse model expressing human CD20 for clinical translation to image NHL.
Topics: Adult; Animals; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Cell Line, Tumor; Chromatography, High Pressure Liquid; Copper Radioisotopes; Dose-Response Relationship, Radiation; Heterocyclic Compounds, 1-Ring; Humans; Isotope Labeling; Lymphoma, Non-Hodgkin; Male; Mass Spectrometry; Mice; Mice, Transgenic; Models, Animal; Organometallic Compounds; Positron-Emission Tomography; Tomography, X-Ray Computed; Translational Research, Biomedical | 2012 |
90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Drug Stability; Female; Heterocyclic Compounds, 1-Ring; Humans; In Vitro Techniques; Isotope Labeling; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Pentetic Acid; Radioimmunotherapy; Radiopharmaceuticals; Reference Values; Tissue Distribution; Tumor Cells, Cultured; Yttrium Radioisotopes | 2003 |
Antibody responses to macrocycles in lymphoma.
Topics: Animals; Antibody Formation; Copper Radioisotopes; Edetic Acid; Female; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Humans; Immunoconjugates; Immunoglobulin G; Indium Radioisotopes; Lymphoma, Non-Hodgkin; Male; Mice; Middle Aged; Radioimmunodetection; Radioimmunotherapy | 1996 |